TechnoPhage announces FDA Fast Track Designation granted to TP-102 for the treatment of patients with infected diabetic foot ulcers.
Phico Therapeutics raises £7 million investment to support SASPject novel engineered phage technology
Phico Therapeutics raises £7 million investment to support SASPject advancement, novel engineered phage technology for next-generation antibiotics to curb antimicrobial resistance (AMR).
Cytophage announced the beginning of animal testing of their throat and nasal phage spray that targets the COVID-19 virus.
TechnoPhage announced the beginning of Phase I/IIa study of TP-102 phage therapy to treat Diabetic Foot Infections (DPI).